Diagnostic utility of reflux disease symptoms

M Shaw

Symptom assessment, by structured interview or questionnaire, is central to the diagnosis of gastro-oesophageal reflux disease (GORD). However, empiric support for the diagnostic utility of reflux symptom measures is lacking. Reliable reflux symptom questionnaires have been developed with content validity. These questionnaires need to be evaluated in terms of diagnostic accuracy, support for application of specific treatment, and improved outcomes resulting from their use. The impact on clinical outcomes of GORD diagnosis by valid questionnaires or structured interview has not been studied.

SUMMARY
Symptom assessment, by structured interview or questionnaire, is central to the diagnosis of gastro-oesophageal reflux disease (GORD). To be of use, it needs to provide an accurate diagnosis, support specific treatment selection and lead to improved outcomes.

Interviewer and questionnaire methods have shown relatively high sensitivities of 70% or more for the diagnosis of GORD, but low specificity. However, a gold standard comparative measure is lacking, and comparison—for example with pH monitoring—risks underestimating the diagnostic accuracy of symptom assessment. Use of a word picture to describe heartburn enhances diagnostic accuracy, and the same may apply for regurgitation and epigastric pain, although this requires detailed scrutiny.

Rigorous development and validation of questionnaires and interviewer methods is underway to enhance diagnostic accuracy. The Reflux Disease Questionnaire is a 12 item questionnaire of three scales (heartburn, regurgitation, and dyspepsia) that is reliable and valid, although diagnostic validity remains to be established. Selection of the predominant symptom has been suggested to improve diagnostic accuracy, but is limited by the inability of most patients to identify a predominant symptom when asked to do so directly.

Selection of the predominant symptom heartburn has been shown to predict response to proton pump inhibitor therapy. Also, endorsement of the individual questionnaire items “burning rising feeling” or “relief from antacids” identifies those more likely to respond. Use of questionnaires, coupled with a trial of treatment in patients thus diagnosed as likely to have GORD, will inevitably show strong support for selection of specific treatments. Although of use to the practitioner, this would not be applicable for most clinical trials.

The impact on clinical outcomes of GORD diagnosis by valid questionnaires or structured interview has not been studied.

INTRODUCTION
Symptoms play a central role in the diagnosis of disease, especially gastro-oesophageal reflux disease (GORD), given the limitations of objective medical testing. Symptom assessment can be achieved by structured interview or questionnaire. Although a structured interview more closely approximates clinical practice, questionnaire possess a number of inherent advantages, especially if automated. Questionnaires minimise interobserver variability and facilitate quantitative assessment of subject responses. Easily scored questionnaires also lend themselves to efficient, inexpensive symptom assessment.

Research on the diagnostic utility of reflux disease symptoms will most likely use questionnaires in the future given these and other advantages.

A useful diagnostic test needs to satisfy three criteria: (1) provide an accurate diagnosis; (2) support application of specific, efficacious treatment; (3) lead to improved outcomes.

Satisfaction of these criteria by the systematic gathering of reflux symptom data will be examined.

ACCURACY OF A SYMPTOM DIAGNOSIS
The accuracy of symptom diagnosis has been examined with interviews and questionnaires in GORD enriched populations. Increasing the prevalence of affected individuals improves the positive predictive value of symptom assessment, but impairs the negative predictive value. The diagnostic utility of reflux disease symptoms should ideally be assessed in an unselected population of symptomatic individuals. In some cases, however, it may be possible to extrapolate the data from selected populations to estimate the accuracy of symptom assessment in an unselected primary care population (see Moayyedi and colleagues in this supplement (page iv55–iv57)).

Interviews by experienced gastroenterologists were used in a study using ambulatory pH monitoring as the gold standard. The interviewers categorised the patients as having equivocal or unequivocal histories of GORD.

Abbreviations: GORD, gastro-oesophageal reflux disease; OTC, over the counter; RDQ, reflux disease questionnaire
The questionnaire and interviewer methods have been validated to overcome the limitations of previous diagnostic methods. Multiple iterations of expert opinion and patient interviewing on completion of item wording, standard psychometric analyses—including multitrait scaling—resulted in a 12 item questionnaire of three scales (heartburn, regurgitation, and dyspepsia) that was reliable and valid. The diagnostic validity of the RDQ remains to be established, however.

An intriguing observation during the development of the RDQ was that patients selected “heartburn” as their predominant symptom significantly more often than the corresponding physician did. This could be due to an inaccurate interpretation of the word “heartburn” as it is not exactly defined in medical literature. Patient interpretation of the word “heartburn” has also been evaluated qualitatively. In Sweden, only 13% of a population with upper gastrointestinal complaints endorsed “heartburn” as their predominant symptom, compared with 40% who acknowledged that the word picture for reflux accurately identified the predominant symptom when responding to a self-report questionnaire.

The reflux disease questionnaire (RDQ) was developed according to established principles of questionnaire design and validation to overcome the limitations of previous questionnaires. Content and wording were developed with feedback from gastroenterologists and patients. A diagnostic treatment trial may increase specificity. Diagnostic treatment trials may increase specificity. Similar considerations have been made in the development of the RDQ, which is designed to identify patients with reflux symptoms who are likely to respond to treatment. The questionnaires and interview methods have been developed and validated following established, rigorous methods.

Enhancing diagnostic accuracy

Multiple approaches have been suggested to enhance the suboptimal diagnostic accuracy of GORD symptom surveys, and rigorous development and validation of questionnaires and interviewer methods is underway. Diagnostic treatment trials may increase specificity. Similar considerations have been made in the development of the RDQ, which is designed to identify patients with reflux symptoms who are likely to respond to treatment.

The RDQ was that the symptom response to self-directed, over the counter (OTC) antacid medications was the strongest predictor of GORD diagnosis (table 2). The predictive power of this single question surpassed that of either RDQ reflux scale. However, the OTC response question showed poor internal validity and internal consistency resulting in its deletion from the final questionnaire. The work of Fass and colleagues also suggests that a structured approach to assessing treatment response may be the preferred diagnostic method. A diagnostic treatment trial using the RDQ to select patients and assess treatment response to standardised treatment with superior acid suppression may retain the observed strength of the OTC response question, without compromising reliability and validity. Response to antisecretory medications, however, would be inappropriate for a reflux questionnaire being used to select GORD patients for trials that compared acid suppressive therapy with an alternative. Selecting patients on the basis that they respond

| Table 1 | Diagnostic accuracy of reflux symptoms |
|---|---|---|---|
|  | Sensitivity (%) | Specificity (%) | Positive predictive value (%) |
| Unequivocal history |  |  |  |
| Heartburn | 73 | 53 | 70 |
| Regurgitation | 66 | 58 | 70 |
| Equivocal history |  |  |  |
| Heartburn | 52 | 52 | 46 |
| Regurgitation | 46 | 45 | 40 |

This selection process had an impact on the diagnostic utility with positive predictive values for the symptoms of heartburn and regurgitation of 70% each in the unequivocal group and 46% for heartburn and 40% for regurgitation in the equivocal group (table 1).

The first questionnaire diagnosis study also used a gold standard for diagnosis, of ambulatory pH monitoring and oesophagogastroduodenoscopy (OGD). The questionnaire consisted of four items with word pictures for the quality, location, and movement of the discomfort along with symptom frequency and response to antacids. Response options were dichotomised and positive responses were required to all four questions for a diagnosis of GORD. Only 33% of subjects referred with presumed GORD had a positive questionnaire diagnosis with these stringent criteria and the positive predictive value was 85%.

This was followed by another study using a different questionnaire, but the same gold standards for diagnosis. The word picture described above was incorporated along with other questions that either supported or detracted from a diagnosis of GORD. Final questionnaire scoring used item weighting assigned by the investigator. A cut off for diagnosis relied on computer modelling of different options. Using the computer derived cut off of 4, a sensitivity of 70% and specificity of 46% was determined in subjects referred for presumed GORD. The authors correctly concluded that it was not appropriate to calculate predictive values in a population enriched for the disease of interest.

Highly accurate diagnosis of GORD has not been demonstrated in any of these studies. Critical to any study of diagnostic accuracy is the comparative measure—the gold standard—used to classify patients as having GORD. Although initially proposed as a “gold standard” for the diagnosis of GORD, 24 hour ambulatory pH monitoring is probably not a gold standard, as sensitivity probably does not exceed 75%. Comparing a new diagnostic method with an inferior standard risks underestimating the accuracy of the new test, as it will always be inferior to the existing standard. The questionnaire and interviewer methods have not been developed and validated following established, rigorous methods.

Formal testing. Patient interpretation of the word “heartburn” highlights the need to do this. Representative patient responses during cognitive interviews for a description of the meaning of the word “heartburn” included “...can feel acid rising...”, “...burning sensation in the stomach...”, “...a bad taste in my mouth...”, and “...painful burning in stomach and whole GI tract...”. Two of these four responses are not consistent with the definition of heartburn: “epigastric/retrosternal burning feeling that rises into the chest”. One is possibly due to regurgitation and the other non-specific abdominal pain.

Patient interpretation of the word “heartburn” has also been evaluated quantitatively. The sensitivity of the word “heartburn” was compared with the word picture “a burning feeling rising from your stomach or lower chest up towards your neck” in a Swedish population. Only 13% of a population with upper gastrointestinal complaints endorsed “heartburn” as their predominant symptom, compared with 40% who acknowledged that the word picture for reflux accurately identified the predominant symptom when responding to a self-report questionnaire.

Inaccurate interpretation of the word “heartburn” was seen in a US population, although the results are not as remarkable. Patients’ questionnaire responses to the word “heartburn” were compared with a gastroenterologist interview where the interviewer had no knowledge of responses to the questionnaire. Overall agreement was 82%. When patients selected “heartburn”, the physician did not agree that the symptom was reflux 12% of the time. In 6% of patients, the physician interpreted the patient’s symptoms as heartburn although the patient did not endorse “heartburn” on the survey. The kappa value of 0.57 indicated fair agreement. Patient interpretation of “heartburn” in the USA showed a less remarkable decline in sensitivity with reduction in specificity being more significant.

Regurgitation and epigastric pain have not received as detailed scrutiny. Excellent agreement was seen when using a description for regurgitation instead of the words “acid regurgitation” compared with a gastroenterologist interview with overall agreement of 88% and kappa of 0.76.

The reflux disease questionnaire (RDQ) was developed according to established principles of questionnaire design and validation to overcome the limitations of previous questionnaires. Content and wording were developed with feedback from gastroenterologists and patients. A diagnostic treatment trial may increase specificity. Diagnostic treatment trials may increase specificity. Similar considerations have been made in the development of the RDQ, which is designed to identify patients with reflux symptoms who are likely to respond to treatment. The questionnaires and interview methods have not been developed and validated following established, rigorous methods.
SUPPORT FOR SPECIFIC TREATMENT SELECTION
GORD symptom questionnaires or structured interviews have received limited study in the application of specific and efficacious treatment. Individual questions and questionnaire total score were examined for the capability to predict symptom response to PPI therapy. The questionnaire total score did not predict response although endorsement of the individual items “burning rising feeling” or “relief from antacids” did identify those who were significantly more likely to respond to treatment. The failure of the questionnaire total score to successfully identify treatment responders limits the diagnostic utility of the questionnaire.

Predominant symptom selection has been shown to predict response to PPI therapy if the predominant symptom is heartburn. Given the compromise in sensitivity as discussed above, such a question adversely affects diagnostic accuracy. In addition, the predominant symptom is dynamic and may change from week to week.

Implementation of treatment trials as part of the diagnostic strategy using questionnaires will inevitably show strong support for selection of specific treatments. This would be useful for the practitioner, but would not be applicable for most clinical treatment trials.

OUTCOMES IMPROVEMENT
Multiple outcomes are of interest to patients and physicians including absence of symptoms, improved health related quality of life, healing of oesophagitis, and maintenance of remission. The impact on these outcomes when GORD diagnosis is facilitated by valid questionnaires or structured interview has not been studied. As studies of endoscopy negative reflux disease show high efficacy when patients are selected by less rigorous measures, it can be reasonably anticipated that validated symptom measures would perform similarly. Such studies will require that the symptom measure is the ultimate criterion leading to subject entry into the trial.

SUMMARY
Despite the importance of symptoms in identifying GORD patients, empiric support for the diagnostic utility of reflux symptom measures is lacking. Reliable reflux symptom questionnaires have been developed with content validity. These questionnaires need to be evaluated in terms of diagnostic accuracy, support for application of specific treatment, and improved outcomes resulting from their use.

REFERENCES